Xeros Helena, Bucak Bilal, Oushy Soliman, Lanzino Giuseppe, Keser Zafer
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
Interv Neuroradiol. 2024 Dec 12:15910199241305423. doi: 10.1177/15910199241305423.
Iatrogenic cervical artery dissection (CeAD) results from various procedures including interventional angiographic procedures and diagnostic angiography. Iatrogenic CeAD is rare, resulting in limited literature on management and outcomes. This observational cohort study investigates approaches and outcomes of iatrogenic CeAD after endovascular interventions.
We conducted a retrospective review for patients who underwent endovascular intervention with resulting iatrogenic CeAD at Mayo Clinic, Rochester, MN, from 1998 to 2021. Pertinent patient factors were extracted and descriptive statistics generated.
Between 1998 and 2021, 21,191 patients underwent catheter-based cerebral angiography. Thirty-two had iatrogenic CeADs (23 women; median age 59 [range 40.5-92.9]). Common comorbidities included hypertension (62.5%), smoking (56.3%), and hyperlipidemia (46.9%). Nine (28.1%) had dissection with diagnostic angiograms, 6 (18.8%) endovascular thrombectomy, 15 (46.9%) intracranial aneurysm treatment/coiling, and 2 (6.3%) intracranial angioplasty with/without stenting. All dissections were diagnosed by cerebral angiography during the same session as initial interventions. Four (12.5%) underwent hyperacute stenting. Thirty (93.7%) were placed on antithrombotic therapy with aspirin alone (34.4%) or dual-antiplatelet therapy with aspirin and clopidogrel (37.5%). Median duration of acute treatment was three months. Follow-up imaging showed excellent radiological course.
Iatrogenic CeAD with endovascular interventions is rare and typically benign. Most are managed medically without complications or long-term negative outcomes. Oral single or dual-antiplatelet therapies are preferred compared to previous studies which emphasize intravenous anticoagulation. The duration of acute therapy varied from three months to lifelong. Key factors influencing clinical decision-making may include occlusion rate, pseudoaneurysm formation, intracranial extension, distal collateral circulation, and resultant ischemia.
医源性颈内动脉夹层(CeAD)可由包括介入性血管造影手术和诊断性血管造影在内的各种手术引起。医源性CeAD较为罕见,导致关于其治疗和预后的文献有限。这项观察性队列研究调查了血管内介入术后医源性CeAD的治疗方法和预后。
我们对1998年至2021年在明尼苏达州罗切斯特市梅奥诊所接受血管内介入治疗并导致医源性CeAD的患者进行了回顾性研究。提取了相关的患者因素并进行描述性统计。
1998年至2021年期间,21191例患者接受了基于导管的脑血管造影。32例发生医源性CeAD(23例女性;中位年龄59岁[范围40.5 - 92.9岁])。常见的合并症包括高血压(62.5%)、吸烟(56.3%)和高脂血症(46.9%)。9例(28.1%)因诊断性血管造影发生夹层,6例(18.8%)接受血管内血栓切除术,15例(46.9%)接受颅内动脉瘤治疗/栓塞,2例(6.3%)接受颅内血管成形术(伴或不伴支架置入)。所有夹层均在初次干预的同一疗程中通过脑血管造影诊断。4例(12.5%)接受超急性期支架置入。30例(93.7%)接受抗血栓治疗,单独使用阿司匹林(34.4%)或阿司匹林和氯吡格雷双联抗血小板治疗(37.5%)。急性治疗的中位持续时间为三个月。随访影像学显示放射学过程良好。
血管内介入治疗导致的医源性CeAD罕见且通常为良性。大多数通过药物治疗,无并发症或长期不良后果。与以往强调静脉抗凝的研究相比,口服单药或双联抗血小板治疗更受青睐。急性治疗的持续时间从三个月到终身不等。影响临床决策的关键因素可能包括闭塞率、假性动脉瘤形成、颅内扩展、远端侧支循环和由此导致的缺血。